Imagine. Invent. Disrupt.

Currently, patients who may benefit from biologic therapies, such as those suffering from retinal diseases like Neovascular Age-Related Macular Degeneration (Wet AMD), may be unable to tolerate or withstand constant injections into the eye, which are required to maintain vision.   

At Starlight Bio, we envision combining our proprietary Starlight delivery platform with the power of non-permanent gene-based treatments to change the entire retinal therapy paradigm of constant eye injections with a new approach that is completely non-invasive and topically administered.  

Without the need for invasive injections, retinal specialists are freed from the operating suite ("chair time") which currently limits the number of patients that can receive treatment.  Importantly, as a non-invasive administration, physician extenders, such as nurse practitioners, will be able to administer  therapy--expanding the availability of retinal treatments even further.

With the Starlight Platform, patients will no longer be bound by the fear of repeated injections into the eye, which can increase the potential for sigh-threatening ocular infections, such as endophthalmitis.

The Starlight Platform makes this impossible dream possible by delivering a retinal therapy of interest in mere minutes, all without the need for  injections.  

In the future, Starlight Bio plans to expand into additional disease areas beyond ophthalmology alone. 

Current treatment for Wet AMD requires chronic, frequent injections of anti-VEGF therapies directly into the eye.  Starlight Bio aims to make eye injections no longer necessary using the non-invasive (no injection) Starlight Platform.